SymlinPen 60 and Tazarotene

• Generic Name: pramlintide
• Dosage Forms: n.a.
• Other Brand Names: SymlinPen 120, SymlinPen 60, Symlin

SymlinPen 60 is a man-made form of a hormone that occurs naturally in the body. This medicine lowers blood sugar in three ways. It slows the rate that food moves from your stomach to your intestines, which keeps your blood sugar from rising too fast. This medicine also lowers the amount of glucose (sugar) your liver produces. Lastly, this medicine triggers the feeling of fullness after meals to help control your appetite and decrease how much food you eat.

SymlinPen 60 is used together with insulin to treat type 1 or type 2 diabetes. This medicine is usually given after other diabetes medicines have been tried without success.

SymlinPen 60 may also be used for purposes not listed in this medication guide.

• Generic Name: tazarotene topical
• Dosage Forms: n.a.
• Other Brand Names: Avage, Fabior, Tazorac

Treatment of stable plaque psoriasis with ≤20% body surface area involvement.

Combination therapy with a mid-or high-potency topical corticosteroid more effective than either agent alone.

0.1% cream or gel more effective in improving psoriasis manifestations; 0.05% cream or gel associated with less local irritation.

Treatment of mild to moderate acne vulgaris.

Efficacy in patients resistant to oral antibiotics or previously treated with other retinoids not established.

Palliative therapy to improve dermatologic changes (e.g., fine wrinkling, mottled hypo- or hyperpigmentation, benign lentigines) associated with photodamage.

Use as an adjunct to a comprehensive skin care plan and sun avoidance program. (See Administration under Dosage and Administration.)

Does not eliminate or prevent wrinkles, repair photodamaged skin, reverse photoaging, or restore youthful or younger dermal histologic pattern. No mitigating effects on severe manifestations of chronic sunlight exposure (e.g., coarse/deep wrinkling, tactile roughness, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, dermal elastosis) demonstrated.

Safety and efficacy not established for use in nonwhite (e.g., Asian, Hispanic) patients or Fitzpatrick skin types V and VI.